South Korea’s Health Insurance and Assessment Service (HIRA) has released its “detailed evaluation criteria for drugs subject to negotiation,” and Australia has been left off the list of countries used for reference pricing. The agency was considering it for inclusion into its’ A7 list, which includes Germany, Switzerland, Japan, Italy, France, the UK, and the US.
According to Lee Han-soo, “The agency initially planned also to include Australia but decided to exclude the country after facing severe backlash from the pharmaceutical industry, which strongly protested the country’s inclusion when setting drug prices. Notably, Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over the government’s plan to reference Australia when setting drug prices on Dec. 5 additionally.”
To read more, click here.
(Source: Korean Biomedical Review, December 30th, 2022)